Oglufanide (disodium)

• UNSPSC Description:

  Oglufanide (H-Glu-Trp-OH) disodium is a dipeptide immunomodulator isolated from calf thymus. Oglufanide disodium inhibits vascular endothelial growth factor (VEGF). Oglufanide disodium can stimulate the immune response to hepatitic C virus (HCV) and intracellular bacterial infections. Oglufanide disodium shows antitumor and anti-angiogenesis activities[1][2][3].

• Target Antigen:

  Endogenous Metabolite; HCV; VEGFR

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Metabolic Enzyme/Protease;Protein Tyrosine Kinase/RTK

• Field of Research:

  Cancer; Infection; Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/oglufanide-disodium.html

• Smiles:

  O=C(O[Na])CC[C@H](N)C(N[C@H](C(O[Na])=O)CC1=CNC2=CC=CC=C12)=O

• Molecular Weight:

  377.30

• References & Citations:

  [1]Bayes M, et al. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Jul-Aug;27(6):411-61.|[2]Nagendra Kumar Kaushik, et al. Biomedical importance of indoles. Molecules. 2013 Jun 6;18(6):6620-62.|[3]Noy A, et al. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol. 2005 Feb 10;23(5):990-8.|[4]Smith DL, et al. Natural killer cell cytolytic activity is necessary for in vivo antitumor activity of the dipeptide L-glutamyl-L-tryptophan. Int J Cancer. 2003 Sep 10;106(4):528-533.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 2

• CAS Number:

  237068-57-4